

Nicola Personeni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6221487/publications.pdf>

Version: 2024-02-01

95
papers

5,347
citations

159585

30
h-index

88630

70
g-index

95
all docs

95
docs citations

95
times ranked

6520
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
2	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	4.1	9
3	Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 198-199.	8.1	4
4	Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 204.	2.5	3
5	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	4.1	3
6	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
7	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	3.7	44
8	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	9.4	48
9	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	4.3	7
10	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. <i>British Journal of Cancer</i> , 2021, 124, 407-413.	6.4	15
11	Systemic treatment of HCC in special populations. <i>Journal of Hepatology</i> , 2021, 74, 931-943.	3.7	72
12	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	3.2	15
13	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
14	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191.	3.7	9
15	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021, 7, 455-463.	1.8	6
16	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	2.7	5
17	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 2315-2324.	2.4	6
18	Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, 896-898.	10.7	1

#	ARTICLE	IF	CITATIONS
19	Are we ready for patient-reported outcomes in hepatocellular carcinoma?. The Lancet Gastroenterology and Hepatology, 2021, 6, 602-603.	8.1	0
20	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939.	2.4	9
21	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers, 2021, 13, 4506.	3.7	11
22	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	2.8	42
23	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665.	3.7	5
24	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
25	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	3.7	47
26	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers, 2020, 12, 3370.	3.7	28
27	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
28	COVID-19 and liver cancer clinical trials: Not everything is lost. Liver International, 2020, 40, 1541-1544.	3.9	3
29	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. Molecular Imaging and Biology, 2020, 22, 1446-1454.	2.6	3
30	Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Science Reports, 2020, 3, e147.	1.5	4
31	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532.	1.7	0
32	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532-1532.	1.7	2
33	Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. Future Oncology, 2019, 15, 2107-2112.	2.4	4
34	Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future Oncology, 2019, 15, 2449-2462.	2.4	11
35	Cabozantinib for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 847-855.	2.4	12
36	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26.	6.5	33

#	ARTICLE	IF	CITATIONS
37	Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 31-39.	3.7	55
38	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	2.4	8
39	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. British Journal of Cancer, 2019, 120, 165-171.	6.4	279
40	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10
41	Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 341-341.	1.6	1
42	Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052.	3.3	92
43	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2019, 11, 788-803.	2.0	8
44	Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 406-406.	1.6	1
45	Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer. , 2019, , .		0
46	Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?. Annals of Surgical Oncology, 2018, 25, 1676-1685.	1.5	35
47	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	10.7	285
48	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. World Journal of Surgery, 2018, 42, 2651-2659.	1.6	27
49	Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?. Cancer Biology and Therapy, 2018, 19, 659-663.	3.4	9
50	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 2018, 17, e489-e498.	2.3	16
51	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-10.	2.2	34
52	Shaping the landscape of immune oncology in hepatocellular carcinoma. Lancet Oncology, The, 2018, 19, 855-856.	10.7	2
53	Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.. Journal of Clinical Oncology, 2018, 36, 487-487.	1.6	2
54	Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
55	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	1.9	80
56	Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 735-742.	1.0	33
57	Regorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 567-576.	2.4	26
58	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. <i>Gastric Cancer</i> , 2017, 20, 428-437.	5.3	5
59	Sorafenib in Hepatitis C Virus "Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2213-2214.	1.6	3
60	Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies. <i>Journal of Oncology Practice</i> , 2017, 13, 368-369.	2.5	15
61	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICCA) with FGFR2 genetic aberrations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4017-4017.	1.6	24
62	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 14408-14415.	1.8	30
63	The behavior of colorectal liver metastases in the time frame between the end of preoperative chemotherapy and liver resection: A new selection criterion for technically resectable patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 665-665.	1.6	0
64	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. <i>Cancer Medicine</i> , 2016, 5, 256-264.	2.8	29
65	Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 197-197.	1.6	3
66	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016, 7, 72622-72633.	1.8	60
67	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, 162-169.	2.3	11
68	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1399-1407.	6.4	33
69	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , 2015, 26, 542-547.	1.2	96
70	Tivantinib for hepatocellular carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 343-351.	0.8	0
71	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. <i>BMC Cancer</i> , 2014, 14, 619.	2.6	86
72	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1179-1187.	2.5	34

#	ARTICLE	IF	CITATIONS
73	The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 97-103.	0.8	11
74	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 55-63.	10.7	522
75	Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2013, 9, 153-165.	2.4	17
76	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2013, 18, 379-380.	3.7	34
77	Reply to Y. Pointreau et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 335-335.	1.6	0
78	Biomarkers in Hepatocellular Carcinoma—Letter. <i>Clinical Cancer Research</i> , 2012, 18, 4861-4861.	7.0	4
79	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012, 65, 218-223.	2.0	35
80	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 101-107.	3.7	191
81	Advanced Colorectal Liver Metastases and Surgery After Preoperative Chemotherapy: Is Response-Based Selection Enough?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2733-2734.	1.6	2
82	Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection. <i>Journal of Clinical Oncology</i> , 2011, 29, e680-e681.	1.6	17
83	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2010, 103, 837-844.	6.4	28
84	Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 3687-3694.	1.6	377
85	Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study. <i>Clinical Cancer Research</i> , 2008, 14, 5869-5876.	7.0	171
86	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. <i>Annals of Oncology</i> , 2008, 19, 508-515.	1.2	738
87	Outcome Prediction to Erlotinib in Gastroesophageal Adenocarcinomas: Can We Improve Epidermal Growth Factor Receptor and Phospho-AKT Testing?. <i>Journal of Clinical Oncology</i> , 2007, 25, 910-910.	1.6	4
88	Achievements in Systemic Therapies in the Pre-genomic Era in Metastatic Breast Cancer. <i>Oncologist</i> , 2007, 12, 253-270.	3.7	85
89	Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 171-177.	1.3	36
90	Epidermal Growth Factor Receptor Gene Copy Number in Esophageal Cancer and Outcome Prediction to Gefitinib: Does Intratumoral Heterogeneity Matter?. <i>Journal of Clinical Oncology</i> , 2006, 24, 5465-5465.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Correlation Between the Response to Cetuximab Alone or in Combination With Irinotecan and the Activated/Phosphorylated Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer. <i>Seminars in Oncology</i> , 2005, 32, 59-62.	2.2	30
92	HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. <i>Cancer</i> , 2003, 99, 310-315.	4.1	42
93	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. <i>European Journal of Immunology</i> , 2001, 31, 3016-3025.	2.9	141
94	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. , 2001, 31, 3016.		3
95	Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, , .	1.3	0